Marcan Ltd

Marcan is focusing on research and product development in three specific areas, namely, Cannabinoids in Degenerative Medicine, Cannabinoids in Pain Management and Cannabinoids for Cancer Treatments.

Cannabinoids in Degenerative Medicine

Cannabis has proven anti-inflammatory and neuroprotective properties. Inflammation plays a major role in not only Alzheimer’s, but motor neurone disease, Parkinson’s, AIDS, dementia, multiple sclerosis, autism, schizophrenia, etc.

Areas of research and treatment regimens extend to these specific areas:

  • Alzheimer’s
  • Motor Neurone Disease
  • Parkinson’s
  • AIDS
  • Dementia
  • Multiple Sclerosis
  • Autism
  • Schizophrenia
Cannabinoids in Pain Management

Chronic pain represents an emerging public health issue of massive proportions, particularly in view of aging populations in industrialised nations. Associated facts and figures are daunting: In Europe, chronic musculoskeletal pain of a disabling nature affects over one in four elderly people, while figures from Australia note that older half of older people suffer persistent pain, and up to 80% in nursing home populations (Gibson 2007). Responses to an ABC News poll in the USA indicated that 19% of adults (38 million) have chronic pain, and 6% (or 12 million) have utilized cannabis in attempts to treat it (ABC News 2005).

Particular difficulties face the clinician managing intractable patients afflicted with cancer-associated pain, neuropathic pain, and central pain states (e.g., pain associated with multiple sclerosis) that are often inadequately treated with available opiates, antidepressants and anticonvulsant drugs. Physicians are seeking new approaches to treatment of these conditions, but many remain concerned about increasing governmental scrutiny of their prescribing practices (Fishman 2006), prescription drug abuse or diversion. The entry of cannabinoid medicines to the pharmacopoeia offers a novel approach to the issue of chronic pain management, offering new hope to many

Marcan is exploring various areas of research and potential treatment regimens to provide effective pain management solutions using Cannabinoids.

Cannabinoids for Cancer Treatments

The anti-cancer properties of THC, CBD, CBG and other cannabinoids are well established. Scientists have been investigating them since the early 1970s and more than 1100 papers on cannabinoids and cancer have been published.

It is also well established that cannabis helps with the side effects of cancer treatments, particularly nausea and lack of appetite. Cannabis may also help alleviate anxiety, depression, insomnia and mood disorders in cancer patients.

A very large quantity of anecdotal reports detail remarkable results with cannabis oil on many different forms of cancer. One of the most important properties of cannabis as a cancer therapy is that it is non-toxic and even if little therapeutic effect is achieved, it causes little harm.

Marcan research and potential treatment regimens extends into several specific areas around cancer therapy including:

  • Nausea
  • Brain Cancer
  • Colorectal Cancer
  • Breast Cancer
  • Tumours in general
  • Lymphoblastic Leukaemia
Hydrogels Ltd

Hydrogels Ltd conducts research into the use of Hydrogels in medicine. The word Hydrogels  refers to a drug delivery system with crosslinked, three-dimensional polymeric networks that have the ability to swell when placed in water or other biological fluid.

The benefits of Hydrogel drug delivery include:

  • Softness, smartness and the capacity to store water but also a reservoir for drug loading encapsulation
  • Programmed to respond to various environmental stimuli in vivo e.g. temperature, pH, electrical modulated system
  • To release a single or multiple therapeutic substance at different site-specific locations
  • Designed as biodegradable system, where it naturally degrades under enzymatic hydrolysis thus release non-toxic metabolites
  • No need for surgical implant operation and surgical removal
  • Drug release rate can be more readily controlled
Vendrove Ltd

Vendrove own a range of Medical Intellectual Property, together with Investment in Stem Cell research and development across a wide range of diseases and conditions. Within Vendrove, there are a number of subsidiary companies, patents and assets which it has varying degrees of ownership interest in, all related to the healthcare sector.

All images are for illustration purposes only and do not represent actual photos for each of the subsidury companies listed